Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Antia Crespo Golmar"'
Autor:
Eloi Franco-Trepat, María Guillán-Fresco, Ana Alonso-Pérez, Miriam López-Fagúndez, Andrés Pazos-Pérez, Antia Crespo-Golmar, Oreste Gualillo, Alberto Jorge-Mora, Susana Belén Bravo, Rodolfo Gómez
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 155, Iss , Pp 113671- (2022)
Osteoarthritis (OA) affects more than 300 million people worldwide and it is about to become the first disabling disease. OA is characterized by the progressive degradation of the articular cartilage but is a disease of the whole joint. Articular inn
Externí odkaz:
https://doaj.org/article/c82a71d6a5344286b231582ba10d64af
Autor:
Antia Crespo Golmar, Ximena Elizabeth Larco Rojas, María Eva Vallejo Pascual, C. Iñiguez, Trinidad Pérez Sandoval, Alejandra López Robles, Carolina Álvarez Castro, Clara Moriano, Elvira Álvarez, Manuel Martín, Ismael González Fernández
Publikováno v:
Abstracts accepted for Publication.
Background: Spondyloarthritis (SpA) is a heterogeneous group of diseases that predominantly affect the axial skeleton, with a debut generally before 45 years. Among the factors favoring radiological progression1 are, among others, high levels of CRP,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fee9a1b0160581031fcf9959e33a749a
https://doi.org/10.1136/annrheumdis-2019-eular.4876
https://doi.org/10.1136/annrheumdis-2019-eular.4876
Autor:
Belén Atienza-Mateo, Esteban Rubio Romero, Ricardo Blanco, Miguel A. González-Gay, Luis Fernández-Dominguez, B. Joven-Ibáñez, Beatriz Arca, Alfonso Corrales, Clara Ventin-Rodriguez, José Luis Martín-Varillas, Jose Campos Esteban, Antia Crespo Golmar, Francisco Ortiz-Sanjuán, Maria Jose Moreno, Manuel Moreno, Eva Galindez, O. Maíz, Rafael Melero, Agusti Sellas-Fernández, Raul Veroz Gonzalez, Enrique Raya, Roberto Daniel Gonzalez Benitez, Olga Rusinovich, Alejandro Escudero Contreras, Emma Beltrán, Vanesa Calvo-Río, Natalia Palmou-Fontana, Javier Loricera, Ximena Elizabeth Larco Rojas, María-Luisa Peral
Publikováno v:
Abstracts accepted for Publication.
Background: Tofacitinib (TOFA) is the first inhibitor of JAK kinases with approval for the treatment of psoriatic arthritis (PsA) in Europe (July 2018)1. ToFA has shown efficacy in refractory patients to anti-TNF2. Objectives: A) to assess efficacy a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6bacfa1479a5769dfa23f37f5a822b1c
https://doi.org/10.1136/annrheumdis-2019-eular.7803
https://doi.org/10.1136/annrheumdis-2019-eular.7803